Global COVID-19 Vaccines Market to Reach 4.2 Billion Doses by 2025
The global market for COVID-19 Vaccines, estimated at 6.4 Billion Doses in the year 2023, is projected to reach 4.2 Billion Doses by 2025.
The COVID-19 Vaccines market in the U.S. is estimated at 285 Million Doses in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of 1 Billion Doses by the year 2025. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach 1.8 Billion Doses by the year 2025.
The emergence of mRNA vaccines marks the beginning of a new era in vaccine development and medical therapies. RNA technology offers numerous benefits and holds potential for addressing future outbreaks. However, there are key challenges to overcome. mRNA vaccines have shown promise in combating not only COVID-19 but also cancer, opening doors for new application areas.
Vaccine passports have risen in importance, aiming to ease COVID-19 restrictions and ensure public safety, with developments focusing on digital certificates for enhanced efficiency. mRNA vaccines are touted to provide better protection against newer variants, prompting discussions around the need for booster doses. Vaccine alliances have been formed to ensure equitable access to supplies worldwide, while licensing and partnership deals are driving vaccine production forward on a global scale.
MARKET OVERVIEW
Global Economic Update
COVID-19 Vaccines - Global Key Competitors Percentage Market Share in 2023 (E)
THE VARIOUS COVID-19 VIRUS VARIANTS
AN OVERVIEW OF COVID-19 VACCINE ROLLOUT
COVID-19 Vaccine Approval Details
COVID-19 Vaccine Funding Details
Pfizer/BioNTech's COVID-19 Vaccine Receives World's First Authorization
UK Clinches the First Position in the World to Approve Pfizer's Vaccine
After UK, Pfizer's Vaccine Gains Approval from the US and EU
UK Clinches the First Position in the World to Approve Pfizer's Vaccine
After UK, Pfizer's Vaccine Gains Approval from the US and EU
After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA
Moderna Kick-Starts Inoculation in the US
AstraZeneca's Vaccine - Third Globally to Obtain Approval
Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Johnson & Johnson's Adenovirus-based COVID-19 Vaccine vis-a-vis Moderna or Pfizer
Russia Commences Mass Vaccination from Mid-December, 2020
China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm
WHO Approves China`s Sinopharm Covid-19 vaccine for Emergency Use
China Issues License for Vaccine Production to Overseas Partners
Brazilian Authorities Approve Sinovac's CoronaVac
AstraZeneca's Covishield and Bharat Biotech's Covaxin Receive Emergency Use Approval in India
Sanofi-GSK to Offer Vaccine at a Discounted Rate
CanSinoBIO Claims No Blood Clot Issues from COVID-19 Vaccine
Novavax Obtains First Authorization for its COVID-19 vaccine
mRNA: A NEW APPROACH TO MEDICINE
mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
RNA Technology: Benefits & Potential for Future Outbreaks
Key Challenges
mRNA Vaccines Could Vanquish COVID-19 and Cancer
Efforts to Target New Application Areas
MARKET DYNAMICS
Rise of Vaccine Passports: Key to Ease COVID-19 Restrictions & Ensure Public Safety
Developments Regarding Digital Certificates
COVID-19 Vaccine Passport: Insights & Progress
Why Digital Format Holds Merits?
mRNA Vaccines Offer More Protection Against Newer Variants
Vaccine Companies Stress on Booster Dose
Vaccine Alliances Ensure Supplies for All
Licensing and Partnership Deals Worldwide Propel Vaccine Production
VACCINES FOR KIDS
Kids: A Key to COVID-19 Controlling Efforts
US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 5-11 Years, and 12 to 15 Years Age
Pfizer Approves Vaccine for Kids Aged 5-11 Years
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns
COVID-19 Vaccine Spikevax Approved for Children aged 12 to 17 in EU
FOCUS ON THE FRONTRUNNERS
Moderna, Inc. (USA)
Pfizer Inc./BioNTech (US/Germany)
AstraZeneca/University of Oxford (The UK)
Johnson & Johnson (USA)
CanSino Biologics, Inc. (China)
China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China)
Sinovac Biotech Ltd. (China)
Novavax, Inc. (USA)
Inovio Pharmaceuticals (USA)
Sanofi/GlaxoSmithKline (France/UK)
INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES
Fair Distribution of COVID-19 Vaccine
Vaccine Nationalism Hampers Equitable Distribution of Vaccines
COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine
COVAX Inks Additional Deals for Global Rollout of COVID-19 Vaccines
African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines
COVAX Advance Market Commitment (AMC)
World Economic Forum to Push COVID-19 Vaccine Production Capability
Pushing Manufacturing Capacity to Fulfil Global Demand
Technology Transfer and Other Payments
KEY VACCINE TECHNOLOGY PLATFORMS
Inactivated Vaccines
Inactivated Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
Protein-Subunit Vaccines
Protein-Subunit Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
Non-Replicating Viral-Vector
Non-Replicating Viral Vector Vaccine in Preclinical Development: As on Nov 19, 2021
Replicating Viral Vector Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
Nucleic Acid Vaccines
RNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021
DNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021
Replicating Bacteria Vector
Live Attenuated Vaccines (LAVs)
Live Attenuated Virus Candidate in Preclinical Studies: As on Nov 19, 2021
Live Attenuated Bacterial Vector Candidate in Preclinical Studies: As on Nov 19, 2021
Virus-like Particle Vaccines
Virus-like Particles (VLP) Vaccine Candidate in Preclinical Development: As on July 27, 2021
WORLD COVID-19 VACCINE BRANDS
SELECT CORPORATE DEVELOPMENTS IN THE COVID-19 VACCINE MARKET: 2021
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
A report from GDToday:
On the evening of May 3, 2024, the Guangzhou Opera House dazzled audiences with the performance of "Marco Polo," a captivating opera commissioned by the esteemed venue. In order to commemorate the 700th anniversary of the...
Garrett Smith, Founder and CEO of Community Capital Technology Inc. ("Community Capital"), will be attending the Milken Institute Global Conference ("MI Global") May 5-8, 2024 in Los Angeles. The event brings together global executives and...
Quarterhill Inc. ("Quarterhill" or the "Company") , a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS")...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review...
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...
F5 announced that it has been singled out as a visionary in API security for its F5 Distributed Cloud Web App and API Protection (WAAP) in Enterprise Management Associates' Vendor Vision 2024 report. The report highlights "must see" security...